Get the Stockscreener App
1.97
2.07%
0.04
Pacific Biosciences Of California Inc stock is traded at $1.97, with a volume of 10.18M.
It is up +2.07% in the last 24 hours and up +14.53% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.93
Open:
$1.87
24h Volume:
10.18M
Relative Volume:
1.08
Market Cap:
$579.80M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.5512
EPS:
-1.27
Net Cash Flow:
$-260.90M
1W Performance:
+0.51%
1M Performance:
+14.53%
6M Performance:
+25.48%
1Y Performance:
-79.82%
1-Day Range:
$1.85
$2.01
1-Week Range:
$1.81
$2.13
52-Week Range:
$1.16
$10.65
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.97 | 579.80M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
Fmr LLC Has $694,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Pacific Biosciences updates executive severance agreements By Investing.com - Investing.com Canada
Pacific Biosciences updates executive severance agreements - Investing.com India
Pacific Biosciences Updates Executive Severance Agreements - TipRanks
Pacific Biosciences of California, Inc. announced that it expects to receive $50 million in funding - Marketscreener.com
Long Read Sequencing Market Industry Dynamics - openPR
Why Pacific Biosciences of California (PACB) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
BNP Paribas Financial Markets Reduces Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Pacific Biosciences names CEO as interim CFO By Investing.com - Investing.com Australia
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap UpHere's Why - MarketBeat
Pacific Biosciences names CEO as interim CFO - Investing.com
Soros Fund Management LLC Grows Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACB (Pacific Biosciences of California) Net Issuance of Pr - GuruFocus.com
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight - Benzinga
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Hold" from Analysts - MarketBeat
PacBio Reports Equity Incentive Awards to New Employees Under Na - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Trading 7.4% HigherShould You Buy? - MarketBeat
Shrimp Hydrolysate Market Set to Surge to $675.9 Million with an Impressive 8.7% CAGR by 2034 - GlobeNewswire Inc.
SOFTBANK GROUP CORP. Acquires Significant Stake in Pacific Biosciences of California Inc - GuruFocus.com
PACB (Pacific Biosciences of California) 3-Year Revenue Gro - GuruFocus.com
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 - Quantisnow
Senvest Management LLC Boosts Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y - MSN
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Sumitomo Mitsui Trust Group Inc. Has $20.17 Million Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Research Analysts Offer Predictions for PACB FY2024 Earnings - MarketBeat
DNA Sequencing Market to Grow by USD 17.34 Billion (2024-2028), Driven by Rising NGS Adoption, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
Pacific Biosciences of California (NASDAQ:PACB) Upgraded by UBS Group to "Hold" Rating - MarketBeat
Pacific Biosciences CCO departs amid restructuring By Investing.com - Investing.com Australia
Pacific Biosciences CCO departs amid restructuring - Investing.com India
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Inc (PACB) Quarterly 10-Q Report - Quartzy
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 5.3% Following Analyst Upgrade - MarketBeat
Pacific Biosciences of California, Inc. Announces Resignation of Susan Kim as Chief Financial Officer, Effective December 6, 2024 - Marketscreener.com
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
UBS Downgrades Pacific Biosciences of California (PACB) - MSN
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates - MSN
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock By Investing.com - Investing.com Nigeria
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock - Investing.com
PacBio’s $459 Million Convertible Note Exchange Offering - Global Legal Chronicle
Scotiabank Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $6.00 - MarketBeat
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):